Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...

Environmental biotechnology is the branch of biotechnology that addresses environmental problems, such as the removal of pollution, renewable energy generation or biomass production, by exploiting ...

Today, we will plunge into the realm of sportswear logos. The top 10 brands will be ranked according to how much they have affected this business. What comes to mind when you think about sportswear?

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) today and set a price target of $110.00. Discover outperforming stocks and invest ...

Prime Minister Narendra Modi on Thursday released the genome sequencing data of 10,000 Indian nationals and said it will be a milestone in the field of biotechnology research. The Genome India ...

Commissions do not affect our editors' opinions or evaluations. Biotech stocks are not for the faint of heart. These highly volatile equities can see stomach-churning price swings, driven by how ...

Biotechnology contributes to this aspect of the plastics industry while providing end-of-life waste management solutions via enzymatic recycling, facilitating monomer recovery under milder conditions ...

Re­gen­eron, mak­er of the block­buster oph­thal­mol­o­gy med­i­cine Eylea, has ac­quired an oc­u­lar biotech, the large bio­phar­ma con­firmed to End­points News on Thurs­day.

2024 was the year of the pri­vate megaround. Nine-fig­ure fi­nanc­ings dom­i­nat­ed biotech’s ven­ture fund­ing land­scape, with 96 such rounds tal­lied by End­points News. The bevy … ...

Ideaya wrote the biggest check. The California-based biotech is paying Jiangsu Hengrui Pharmaceuticals $75 million upfront for rights to a DLL3-directed ADC outside of greater China. Hengrui is ...

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t ...